-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Under the changing industry environment, the pharmaceutical rivers and lakes are surgi.
While batches of pharmaceutical companies announced the departure of executives, some pharmaceutical companies also announced the news of the arrival of new executiv.
Recently, a number of pharmaceutical companies have announced news of new executives, and only on August 3, two pharmaceutical companies welcomed female executiv.
Sinopharm: Welcome a new general manager Sinopharm announced that after passing the review by the nomination committee of the company's board of directors, and after deliberation and approval at the 25th meeting of the company's eighth board of directors, the board of directors agreed to appoint .
Hu Huidong as the company's general manag.
According to the company's previous announcement, the senior executives of China Pharmaceutical changed frequently during the ye.
Among them, on July 28, the company announced that its board of directors received written resignation reports from director and general manager Wang Hongxin and deputy general managers Yuan Yingsheng and Chen Ji.
The above three all resigned due to job adjustment reasons, but Wang Hongxin and Yuan Yingsheng will no longer hold any positions in the company after their resignati.
Chen Jing will continue to work as a research manager in the compa.
.
Hu Huidong's resume shows that she is 46 years old and a graduate stude.
Former General Manager of COFCO Land Tianjin Regional Company, General Manager of COFCO Joy City Holdings Tianjin Regional Company, Deputy Director of Human Resources Department (Party Organization Department) of China General Technology (Group) Holding .
, L.
; Deputy Secretary of the Party Committ.
According to the data, Sinopharm is an enterprise dedicated to the development of the pharmaceutical industry and the cause of human health, and strives to build China's pharmaceutical and health indust.
In recent years, the company has initially established an integrated industrial structure of trade, industry, technology and service, led by international trade, supported by the pharmaceutical industry, and linked by pharmaceutical busine.
The industrial form involves planting and processing, research and development, production, sales, logisti.
, import and export trade, academic promotion, technical services and other whole industry cha.
The 2021 annual report shows that China Pharmaceutical achieved operating income of 3234 billion yuan, a year-on-year decrease of 83%; net profit was 647 million yuan, a year-on-year decrease of 56
It is reported that the sharp drop in its net profit is related to the pressure on its main busine.
Keyue Pharma: Welcome to the new President of China and Asia R&D and Operations Keyue Pharma announced the appointment of .
Yan Hui as the R&D and Operations President of Keyue Pharma China and Asia; Responsible for the company's clinical development strategy and execution in China and Asia, as well as operational excellence manageme.
According to the data, .
Yan Hui has extensive experience in the pharmaceutical indust.
Before joining Keyue Medicine, she held important management positions in dMED-Clinipace, Millennium (Takeda Oncology) Asia Development Center, BMS China, GSK China,e.
In addition, he served as the Senior Director of R&D and Regulations of the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment, actively promoting the establishment of China's pharmaceutical R&D innovation ecosystem, the international integration of regulatory regulations and the improvement of R&D quali.
At the same time, support China to join ICH and become a member of ICH Management Committ.
Its new addition, Keyue Pharma, is a clinical development-stage global biotechnology company and a pioneer in complement-targeted therapy for immune-mediated diseas.
With its own LOGIC drug discovery platform, the company is committed to advancing first-in-class therapies (FICs) and best-in-class therapies (BICs) to overcome various challenges in complement drug development, and the company has developed nine innovations targeting complement targets pipeli.
Conclusion "Her strength" can hold up half the sky, is the backbone of the society, and is not allowed in the medical fie.
As more and more female executives speak out in the pharmaceutical industry, it can be seen that women are playing an increasingly prominent role in listed companies and playing an increasingly important ro.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
While batches of pharmaceutical companies announced the departure of executives, some pharmaceutical companies also announced the news of the arrival of new executiv.
Recently, a number of pharmaceutical companies have announced news of new executives, and only on August 3, two pharmaceutical companies welcomed female executiv.
Sinopharm: Welcome a new general manager Sinopharm announced that after passing the review by the nomination committee of the company's board of directors, and after deliberation and approval at the 25th meeting of the company's eighth board of directors, the board of directors agreed to appoint .
Hu Huidong as the company's general manag.
According to the company's previous announcement, the senior executives of China Pharmaceutical changed frequently during the ye.
Among them, on July 28, the company announced that its board of directors received written resignation reports from director and general manager Wang Hongxin and deputy general managers Yuan Yingsheng and Chen Ji.
The above three all resigned due to job adjustment reasons, but Wang Hongxin and Yuan Yingsheng will no longer hold any positions in the company after their resignati.
Chen Jing will continue to work as a research manager in the compa.
.
Hu Huidong's resume shows that she is 46 years old and a graduate stude.
Former General Manager of COFCO Land Tianjin Regional Company, General Manager of COFCO Joy City Holdings Tianjin Regional Company, Deputy Director of Human Resources Department (Party Organization Department) of China General Technology (Group) Holding .
, L.
; Deputy Secretary of the Party Committ.
According to the data, Sinopharm is an enterprise dedicated to the development of the pharmaceutical industry and the cause of human health, and strives to build China's pharmaceutical and health indust.
In recent years, the company has initially established an integrated industrial structure of trade, industry, technology and service, led by international trade, supported by the pharmaceutical industry, and linked by pharmaceutical busine.
The industrial form involves planting and processing, research and development, production, sales, logisti.
, import and export trade, academic promotion, technical services and other whole industry cha.
The 2021 annual report shows that China Pharmaceutical achieved operating income of 3234 billion yuan, a year-on-year decrease of 83%; net profit was 647 million yuan, a year-on-year decrease of 56
It is reported that the sharp drop in its net profit is related to the pressure on its main busine.
Keyue Pharma: Welcome to the new President of China and Asia R&D and Operations Keyue Pharma announced the appointment of .
Yan Hui as the R&D and Operations President of Keyue Pharma China and Asia; Responsible for the company's clinical development strategy and execution in China and Asia, as well as operational excellence manageme.
According to the data, .
Yan Hui has extensive experience in the pharmaceutical indust.
Before joining Keyue Medicine, she held important management positions in dMED-Clinipace, Millennium (Takeda Oncology) Asia Development Center, BMS China, GSK China,e.
In addition, he served as the Senior Director of R&D and Regulations of the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment, actively promoting the establishment of China's pharmaceutical R&D innovation ecosystem, the international integration of regulatory regulations and the improvement of R&D quali.
At the same time, support China to join ICH and become a member of ICH Management Committ.
Its new addition, Keyue Pharma, is a clinical development-stage global biotechnology company and a pioneer in complement-targeted therapy for immune-mediated diseas.
With its own LOGIC drug discovery platform, the company is committed to advancing first-in-class therapies (FICs) and best-in-class therapies (BICs) to overcome various challenges in complement drug development, and the company has developed nine innovations targeting complement targets pipeli.
Conclusion "Her strength" can hold up half the sky, is the backbone of the society, and is not allowed in the medical fie.
As more and more female executives speak out in the pharmaceutical industry, it can be seen that women are playing an increasingly prominent role in listed companies and playing an increasingly important ro.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
